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and Juan Forteaa,b,c,∗
aMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute
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Abstract.
Background: Alzheimer’s disease (AD) is the main medical problem in older adults with Down syndrome (DS). Studies
of cerebrospinal fluid (CSF) AD biomarkers are limited and the feasibility of lumbar puncture (LP) is controversial in this
population.
Objective: To analyze the frequency of complications after a LP in DS.
Methods: We collected data from 80 adults with DS that underwent a LP within the Down Alzheimer Barcelona Neuroimaging
Initiative. Demographics, cognitive status, headache history, and presence of complications after the LP were recorded in
every subject. In 53 of them (active group), this information was collected following a semi-structured and validated protocol
that actively looks for complications. Other variables related to the LP procedure were also recorded. A telephone interview
to the caregiver was performed 5–7 days after the procedure to ask about complications. Data from 27 subjects (clinical
practice group), from whom the presence of complications was obtained in a medical follow-up visit within the three months
after the LP, were also included.
Results: There were no adverse events in 90% of our participants. The most frequent complication was headache (6.25%);
only one subject reported a typical post-lumbar puncture headache with moderate severity that required analgesic treatment.
Dizziness (3.75%) and back pain (1.25%) were also reported. All the participants that reported complications belonged to
the active group.
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Conclusion: LP can be safely performed to study CSF biomarkers in DS. The reported complications are qualitatively
similar to the general population, but are less frequently reported, even when actively searched for.
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INTRODUCTION
Down syndrome (DS) is the most frequent genet-
ically determined form of intellectual disability [1].
Its pathogenesis relies on the trisomy of chromosome
21 which associates multiple comorbidities [2, 3].
Following the advances in medical and general care
sciences, life expectancy of individuals with DS has
dramatically increased [4–6] and, in consequence, the
incidence of age-associated comorbidities has also
augmented [7].
The International Working Group-2 criteria for
the preclinical states of Alzheimer’s disease (AD)
consider DS as a genetically determined form of
AD [8]. Thus, AD comprises the most important
medical problem in adults with DS [1]. The patho-
physiological mechanism of AD in DS seems to
rely on the overexpression of some genes involved
in the amyloidogenic pathway that are also encoded
by chromosome 21, such as amyloid precursor pro-
tein [9, 10]. Epidemiological studies have found a
prevalence of dementia of 55% between 40–49 years
[11], 77% between 60–69 years, and 100% in peo-
ple aged more than 70 years [12]. However, despite
this exponential increase in dementia prevalence after
age forty, the onset of AD is highly variable and may
depend upon genetic and environmental factors [13].
The diagnosis of dementia in DS is more difficult
than in the general population due to the intellectual
disability associated to the syndrome and because the
clinical presentation might differ from that in the gen-
eral population. Clinical symptomatology can present
as a decline in memory as in the general population,
but frequently starts with changes in personality and
behavior disturbances or it can start with declines in
other cognitive domains such as dysexecutive symp-
tomatology [1, 10, 11]. These atypical presentations,
together with the frequent medical and psychiatric
comorbidities, may complicate the differential diag-
nosis of AD in DS.
Biomarkers, therefore, might prove especially
useful in this population. Cerebrospinal fluid
(CSF) biomarkers such as amyloid-1-42, tau, and
phosphorylated tau allow the tracking of neu-
ropathological features of AD [14–16]. The study
of CSF biomarkers, especially in those atypical
presentations, could help to achieve an earlier diag-
nosis of AD and a more appropriate management of
the patient.
The feasibility of lumbar puncture (LP) to analyze
CSF biomarkers in sporadic AD has been already
addressed [17, 18] and proven safe in the general
population. Post-lumbar pressure headache (PLPH)
is the most frequent complication, affecting up to 25%
patients that undergo a LP. However, only less than
5% patients report a significant complication, such
as severe headache, or need medical treatment. Other
mild complications include back pain, dizziness, and
nausea [17, 18].
The performance of a LP in DS for AD diagnosis
remains controversial and the safety of LP has not
been studied in this population. Our primary aim was
to determine the frequency of complications of LP
to study CSF AD biomarkers in DS. Our secondary
objective was to perform an exploratory analysis on
the factors that were associated with complications.
METHODS
All subjects were recruited at the Barcelona Down
Medical Center (BDMC) in Barcelona between
February 2013 and July 2016. The BDMC is a non-
profit organization that assists about 2,000 subjects
with DS living in Catalonia. In 2014, together with
the Memory Unit of Sant Pau Hospital, a health plan
to screen for AD dementia in adults with DS was
launched. This health plan includes yearly clinical,
neurological, and neuropsychological assessments.
The neuropsychological evaluation uses the Cam-
bridge Examination for Mental Disorders of Older
People with Down’s Syndrome and Others with Intel-
lectual Disabilities battery (CAMDEX-DS), which
is a validated tool to assess cognitive impairment
(CI) in subjects with DS [19–21]. Based on the
neurological visit and the neuropsychological assess-
ment, subjects were classified in four groups based
on their cognitive status: DS-without CI (DS-wCI),
when there is no evidence of impairment of cognitive
functions; DS-non-neurodegenerative etiology (DS-
ndeg), when there is a cognitive impairment most
probably due to a medical or psychiatric comorbidity;
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DS-prodromal AD (DS-pAD), when there is an evi-
dence of cognitive impairment which does not meet
criteria for dementia; and DS-AD when there is a
full blown AD dementia. In the setting of this health
plan, subjects are invited to participate in a clini-
cal research project named DABNI (Down syndrome
Alzheimer Neuroimaging Initiative Program). This
initiative consists of a multimodal AD biomarkers
study in DS with the aim of understanding the AD nat-
ural history in DS. These biomarker studies include
a LP for CSF analysis.
The study has been carried out in strict accordance
with international ethical guidelines for medical
research in humans. This protocol was reviewed and
initially approved by the local independent Ethics
Committee and reported to the Minister of Justice
according to the Spanish law for research in people
with intellectual disabilities in September 2012. It
was performed according to the stipulations made in
the updated Declaration of Helsinki. All participants
were included after obtaining the written informed
consent approved by the ethics committee from both
the legal representative and the subject when the par-
ticipant was able to consent. Before including any
subject in the study, the investigator informed the
participant and their legal tutor of the objectives,
methods, and potential risks of the study or any incon-
venience this may cause. The level of protection of
confidentiality concerning personal data was ensured
as required by the Spanish law (LOPD 15/1999).
We prospectively collected data from those par-
ticipants who underwent a LP. In every case, a
neurologist with expertise in the procedure carried out
the LP. The procedure was performed either in sitting
or lying position, using the pen-point “atraumatic”
needle (Whitacre-22G) or the cutting-edge Quincke
needle (20G or 22G), introducing the bevel parallel
to dural fibers. Patient positioning and needle char-
acteristics were decided based on the neurologist’s
preference according to each patient’s characteris-
tics. CSF was collected by free-flow/dripping. All
participants received similar recommendations after
the procedure: they were advised to rest 24 hours after
the LP and to increase fluid intake.
According to the method of recording the presence
of complications, participants were divided in two
groups (Fig. 1):
–Active group: An active search for complications
was performed; data were systematically collected
following the protocol of a larger international ini-
tiative led by the Alzheimer’s Association and the
University of Gothenburg [17, 18]. Five to seven days
after the LP, caregivers were contacted to answer a
semi-structured telephone interview about complica-
tions. The protocol also registered variables related to
the moment of the LP: position, needle characteris-
tics, patient positioning, needle type, volume of CSF
extracted, attempts needed for CSF removal, visu-
ally hematic CSF staining, and resting time after CSF
acquisition.
–Clinical practice group: The information of the
presence of complications was obtained in a medi-
cal follow-up visit performed within the next three
months after the LP. Data related to the moment of
the LP were not systematically recorded.
In both groups, demographic information, intel-
lectual disability grade (DSM-5 criteria), cognitive
status, previous history of headache, and the presence
of complications were registered in every subject.
The outcome variables that were systematically
obtained included headache, local back pain, dizzi-
Fig. 1. Flow-chart of participants and reported complications.
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ness, and nausea, but other possible complications
could be registered if present. Regarding headache;
we recorded intensity of the pain, defined as mild
(no treatment or mild analgesics), moderate (patient
had to stay in bed for periods of the day), or severe
(invalidating or requiring hospitalization); headache
duration (<2 days, 2–4 days, >4 days); and headache
classification as fulfilling the International Headache
Society criteria of PLPH [18] or as non-specific.
We started to perform LPs in patients with DS
before the implementation of the referred protocol.
This group reflects better the usual clinical (and
research) practice, since participants do not usually
undergo a structured protocol and calls to actively
look for complications. Therefore the later group
allowed us to perform a comparison with the usual
clinical practice.
Statistical analyses were performed with the
software Statistical Package for the Social Sci-
ences v.23.0 (http://www-01.ibm.com/software/es/
analytics/spss/). We analyzed the differences in the
frequency of complications using Chi-Square tests
for categorical and t-student tests for continuous vari-
ables. Variables with p-values <0.20 in the bivariate
analysis and/or with clinical interest were included
in logistic multivariate regression model. Variables
with p-values <0.05 were considered statistically
significant.
RESULTS
Data from 81 consecutive participants were col-
lected for this study: 53 from the active group and
28 from the clinical practice group. One subject in
the clinical practice group was excluded due to the
impossibility of being contacted after the LP (Fig. 1).
Demographics are summarized in Table 1. Subjects
in the active group were younger than those in the
clinical practice group (p = 0.016).
There were no reported complications in 90% of
the participants in the overall sample. Headache was
the most frequent complication, affecting 5 (6.3%)
participants. Dizziness was present in 3 subjects
(3.75%) and 1 in of them (1.3%) back pain was
also referred. No other complications were reported.
All the participants that presented any complication
belonged to the active group, whose procedural char-
acteristics and type of complications are shown in
Table 2. The frequency of complications was, thus,
higher in the active than in the clinical practice group
(p = 0.046).
With respect to headache, a typical PLPH with
moderate severity occurred in 1 subject (1.3%). The
remaining 4 (5%) had a mild unspecific headache. In
the patient diagnosed with PLPH, the pain started in
the first 24 hours after the procedure, required treat-
ment with acetylsalicylic acid, and remitted between
2 and 4 days later. Among the 4 patients with an
unspecific headache, the pain started in the first 24
hours in 3 subjects and 24 hours after the procedure
in one. The duration of the pain was less than 24 hours
in three patients—one of them was recommended to
drink a caffeinated beverage—and between 1 and 2
days in one. A previous history of a mild sporadic
headache was present in 2 subjects (20% of those
who presented headache after LP).
Table 1
Demographics of the participants
Variable Active group Clinical practice group p value
(n = 53) (n = 27)
Age, mean (SD) 41.85 (11.95) 44.63 (8.63) 0.016
Gender, n (%) Male 29 (54.7%) 18 (66.7%) 0.305
Female 24 (45.3%) 9 (33.3%)
Weight, mean (SD)∗ 62.90 (10.67) 64.94 (10.1) 0.470
Intellectual disability, n(%) Mild 10 (18.9%) 4 (14.8%) 0.800
Moderate 29 (54.7%) 18 (66.7%)
Severe 11 (20.7%) 3 (11.1%)
Profound 3 (5.7%) 2 (7.4%)
Diagnosis, n (%) DS-wCI 28 (52.8%) 15 (55.6%) 0.725
DS-ndeg 3 (5.7%) 3 (11.1%)
DS-pAD 9 (17%) 3 (11.1%)
DS-AD 13 (24.5%) 6 (22.2%)
Complications, n (%) No 45 (84.9%) 27 (100%) 0.046
Yes 8 (15.1%) 0 (0%)
AD, Alzheimer’s disease; DS, Down Syndrome; ndegCI: non-neurodegenerative cognitive impairment; pAD, Prodromal Alzheimer’s disease;
wCI, without cognitive impairment. ∗Weight data were obtained from 46 patients of the active group and 24 subjects of the clinical practice
group.
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Table 2
Procedure characteristics and complications recorded in the active
group (n = 53)
Variable
Headache history, n (%) No/rarely 51 (96.2%)
Mild/now and then 2 (3.8%)
Yes/chronic or relapsing 0 (0.0%)




Position, n (%) Lateral decubitus 9 (17.0%)
Sitting 44 (83.0%)
Volume, mL (mean-SD) 12.04 (4.19)
Complications, n (%) No 45 (84.9%)
Yes 8 (15.1%)




Headache type, n (%) No headache 48 (90.6%)
Typical PLPH 1 (1.9%)
Unspecific 4 (7.5%)
Back pain, n (%) No 52 (98.1%)
Yes 1 (1.9%)
Dizziness, n (%) No 50 (94.3%)
Yes 3 (5.7%)
PLPH, post-lumbar puncture headache; Q, Quincke; W, Whitacre.
Table 3
Bivariate analysis of variables obtained from the active group
Complications









Intellectual disability 1.172 (0.425–3.228)
0.252
Headache history 0.118 (0.055–0.249)
Yes/No 0.020










Hematic CSF 3.900 (0.734–20.709)
Yes/No 0.124
Rest after procedure 7.429 (3.729–14.798)
≤1 h/>1 h 0.151
∗Weight data were obtained from 46 patients of the protocol
group.
From the patients that suffered complications,
intellectual disability was mild in 1 subject, moder-
ate in 6, and severe in 1. The cognitive status of those
subjects was DS-wCI in 6, DS-prodromal AD in 1,
and DS-AD in 1.
We performed an exploratory analysis to study the
association between the presence of complications
and the recorded variables (Table 3). Age, weight,
and intellectual disability degree did not show a sta-
tistically significant association with the occurrence
of complications. In bivariate analysis, older subjects
did show a lower risk of headache after the LP, but
this effect was not present in the multivariate analysis.
We also did not find any association between gender
and the occurrence of complications. Previous history
of headache showed a statistically significant associa-
tion with the outcome in the bivariate analysis, but not
in the multivariate regression analysis. The cognitive
status did not affect the occurrence of complications.
Among the variables related to the procedure, the
patient positioning, needle type and diameter, number
of attempts, volume of CSF extracted, hematic CSF,
and rest after LP were not significantly associated
with the presence of complications.
DISCUSSION
Our study indicates that LP is a safe technique to
evaluate CSF AD biomarkers in DS. In our global
sample, 90% of the participants did not report any
complication. When actively looking for them (active
group), headache was the most frequent event, occur-
ring in 9.4% of the subjects, but it was mild in most
cases. Only 1 (1.9%) patient reported a typical PLPH
that had a moderate severity and required treatment
with a common analgesic drug. Dizziness and lumbar
pain were other less frequent complications. No com-
plication was reported in the clinical practice group.
Previous studies in the general population have
reported headache prevalence after the LP ranging
from 5% to 40% [17, 18, 22–30]. However, these
studies used different methodologies. The frequency
of complications differs in those studies using sys-
tematic protocols from those using data collected
in the normal clinical practice [23, 26]. A recall
bias might influence the absence of complications
in this later group. Those studies in the general
population that used the same systematic protocol
from the Alzheimer’s Association and the University
of Gothenburg [17, 18] reported higher frequencies
(36% and 31%) than that found in our study. Further-
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more, the incidence of complications reported by our
active group was significantly higher compared to the
clinical practice group, where these complications
were not actively searched. Consequently, it is not
possible to rule out an infra-report of complications,
mainly in the clinical practice group. This bias in the
report of complications might be especially important
in DS. Individuals with DS frequently present with
unnoticed comorbidities. In many instances, when a
medical comorbidity is found in a routine medical
evaluation, neither the patient nor caregivers actively
complain [31, 32]. The increased difficulty in report-
ing symptoms might be explained by the difficulties
in language, especially in expressive language [33]
and by the fact that many symptoms might be incor-
rectly associated with the syndrome itself and not
with a new comorbidity. Difference in pain percep-
tion is another possibility that might account. There
is a controversy about whether pain perception dif-
fers in individuals with DS from that in the general
population. There are studies that suggest that sub-
jects with DS have decreased sensitivity to pain [34],
while others support that their sensitivity is increased
[34, 35]. In any case, the difference of complications
found between the clinical practice group and the
active group supports the need to actively search for
any medical condition in subjects with DS.
In our exploratory analysis, we did not find any
variable that was significantly associated with the
presence of complications after LP. The small sam-
ple size had probably limited the statistical power,
demanding a cautious interpretation of these results.
In this respect, the studies comparing pen-point
needles with respect to cutting-edge needles have
consistently found lower frequencies of headache in
the atraumatic needles [24, 36, 37]. In addition to
the small sample size, it is worth mentioning that we
predominantly used the atraumatic pen-point needle
(66% versus 34% with cutting-edge needle) in our
sample. This pen-point needle is the one currently
recommended for routine clinical practice and is now
routinely used in our center [38, 39].
The main limitation of this study is the small sam-
ple size. The search for those factors associated with
the presence of complications after the LP was lim-
ited by the small sample size in our study with respect
to previous works [17, 18, 22, 23, 28–30]. However,
this study gathered the largest sample of subjects with
DS that have undergone a LP and it is the first study
to address the feasibility of LP in individuals with
DS in a systematic fashion. Other limitations are the
fact that we did not systematically collect information
regarding the amount of resting time after discharge
and that we only asked the caregivers about the com-
plications and not the subjects directly, which might
have prevented finding a complication.
Our study supports the safety of LP in the study
of AD in DS patients. The use of this technique
in clinical research will enable the use of CSF AD
biomarkers in DS to study the natural history of AD
in DS and will enable earlier and better AD diagnosis
in this population.
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Carmona-Iragui M, Álvarez RM, Fortea J, Balasa M,
Morenas-Rodriguez E, Lladó A, Grau O, Blennow K, Lleó
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Patterns of performance on the modified Cued Recall Test
in Spanish adults with down syndrome with and without
dementia. Am J Intellect Dev Disabil 120, 481-489.
[22] Vilming ST, Kloster R, Sandvik L (2001) The importance
of sex, age, needle size, height and body mass index in post-
lumbar puncture headache. Cephalalgia 21, 738-743.
[23] Hammond ER, Wang Z, Bhulani N, McArthur JC, Levy M
(2011) Needle type and the risk of post-lumbar puncture
headache in the outpatient neurology clinic. J Neurol Sci
306, 24-28.
[24] Lavi R, Yarnitsky D, Rowe JM, Weissman A, Segal D, Avivi
I (2006) Standard vs atraumatic Whitacre needle for diag-
nostic lumbar puncture: A randomized trial. Neurology 67,
1492-1494.
[25] Spriggs DA, Burn DJ, French J, Cartlidge NE, Bates D
(1992) Is bed rest useful after diagnostic lumbar puncture?
Postgrad Med J 68, 581-583.
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D, Martı́nez-Vilavella G, Amor M, Deus J, Rodrı́guez J,
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